Early Preservation of CXCR5 + PD-1 + Helper T Cells and B Cell Activation Predict the Breadth of Neutralizing Antibody Responses in Chronic HIV-1 Infection
Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infe...
Saved in:
Published in | Journal of virology Vol. 88; no. 22; pp. 13310 - 13321 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
01.11.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5
+
CD4
+
T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5
+
CD4
+
T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5
+
CD4
+
T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of
AICDA
than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5
+
CD4
+
T cells. Thus, the early preservation of CXCR5
+
CD4
+
T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection.
IMPORTANCE
Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5
+
PD-1
+
CD4
+
T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5
+
PD-1
+
CD4
+
T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection. |
---|---|
AbstractList | Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5+ CD4+ T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5+ CD4+ T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5+ CD4+ T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5+ CD4+ T cells. Thus, the early preservation of CXCR5+ CD4+ T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection. IMPORTANCE Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5+ PD-1+ CD4+ T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5+ PD-1+ CD4+ T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection. Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5 + CD4 + T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5 + CD4 + T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5 + CD4 + T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5 + CD4 + T cells. Thus, the early preservation of CXCR5 + CD4 + T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection. IMPORTANCE Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5 + PD-1 + CD4 + T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5 + PD-1 + CD4 + T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection. Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5(+) CD4(+) T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5(+) CD4(+) T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5(+) CD4(+) T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5(+) CD4(+) T cells. Thus, the early preservation of CXCR5(+) CD4(+) T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection.UNLABELLEDMuch is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5(+) CD4(+) T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5(+) CD4(+) T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5(+) CD4(+) T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5(+) CD4(+) T cells. Thus, the early preservation of CXCR5(+) CD4(+) T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection.Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5(+) PD-1(+) CD4(+) T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5(+) PD-1(+) CD4(+) T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection.IMPORTANCEBroadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5(+) PD-1(+) CD4(+) T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5(+) PD-1(+) CD4(+) T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection. Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5(+) CD4(+) T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5(+) CD4(+) T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5(+) CD4(+) T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5(+) CD4(+) T cells. Thus, the early preservation of CXCR5(+) CD4(+) T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection. Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5(+) PD-1(+) CD4(+) T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5(+) PD-1(+) CD4(+) T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection. |
Author | Stamatatos, Leonidas Cohen, Kristen Altfeld, Marcus Alter, Galit |
Author_xml | – sequence: 1 givenname: Kristen surname: Cohen fullname: Cohen, Kristen organization: Seattle Biomedical Research Institute, Seattle, Washington, USA, University of Washington, Department of Global Health, Seattle, Washington, USA – sequence: 2 givenname: Marcus surname: Altfeld fullname: Altfeld, Marcus organization: Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Boston, Massachusetts, USA, Heinrich-Pette-Institut, Hamburg, Germany – sequence: 3 givenname: Galit surname: Alter fullname: Alter, Galit organization: Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Boston, Massachusetts, USA – sequence: 4 givenname: Leonidas surname: Stamatatos fullname: Stamatatos, Leonidas organization: Seattle Biomedical Research Institute, Seattle, Washington, USA, University of Washington, Department of Global Health, Seattle, Washington, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25210168$$D View this record in MEDLINE/PubMed |
BookMark | eNqNUk1vEzEUtFARTQM3zshHJNhie-39uCClSyFBFVRVqXqzHPttY7Sxg-1USv9K_yxOGipAHDg9S54Zj9_METpw3gFCLyk5ppQ17z5fzY4Jo01VUP4EjShpm0IIyg_QiBDGClE214foKMbvhFDOK_4MHTLBKKFVM0L3pyoMG3weIEK4Vcl6h32Pu-vuQuA3-PxDQfOYwrCCgC9xB8MQsXIGn-zOeKKT3dOyhrE64bQAfBJAmbTYSn2BdQpqsHfW3eCJS3buzQZfQFx5FyFi63C3CN5Zjaezq_zczPWgt4rP0dNeDRFe7OcYfft4etlNi7Ovn2bd5KzQnNapUFrXUJq6bYguW9P0dQtczAWQVum6aRinylSCsNpQPq_7mhimmdagNBdVS8oxev-gu1rPl2A0uK1huQp2qcJGemXlnzfOLuSNv5Wc8ZaSMgu83gsE_2MNMcmljTqvRznw6yhpVYq87pzMf0CpYBWhmTJGr3639ejnV3gZ8PYBoIOPMUD_CKFEbrshczfkrhuS8gxnf8G1Tbvo8qfs8G_ST6Qyu08 |
CitedBy_id | crossref_primary_10_3389_fimmu_2017_01338 crossref_primary_10_3389_fimmu_2023_1270908 crossref_primary_10_1097_QAI_0000000000001152 crossref_primary_10_3389_fimmu_2018_01901 crossref_primary_10_1093_femspd_ftz044 crossref_primary_10_1099_jgv_0_001016 crossref_primary_10_1111_imr_12501 crossref_primary_10_1186_s12977_018_0433_2 crossref_primary_10_1111_imr_12502 crossref_primary_10_2174_1570162X15666171124122044 crossref_primary_10_1111_imr_12504 crossref_primary_10_3389_fimmu_2022_959002 crossref_primary_10_1016_j_immuni_2015_12_011 crossref_primary_10_1038_s41467_022_29511_1 crossref_primary_10_1097_COH_0000000000000359 crossref_primary_10_1097_COH_0000000000000557 crossref_primary_10_1097_COH_0000000000000317 crossref_primary_10_1128_JVI_01685_18 crossref_primary_10_1016_S2055_6640_20_30497_0 crossref_primary_10_1097_COH_0000000000000552 crossref_primary_10_1097_COH_0000000000000554 crossref_primary_10_3389_fimmu_2017_00046 crossref_primary_10_3389_fimmu_2016_00501 crossref_primary_10_1016_j_jim_2020_112901 crossref_primary_10_1016_j_celrep_2016_10_085 crossref_primary_10_1128_JVI_00659_18 crossref_primary_10_7448_IAS_19_1_21136 crossref_primary_10_3389_fimmu_2018_01975 crossref_primary_10_3389_fimmu_2020_608003 crossref_primary_10_3389_fimmu_2022_837921 crossref_primary_10_1016_j_virol_2020_03_003 crossref_primary_10_1371_journal_pone_0175570 crossref_primary_10_1016_j_ebiom_2020_102727 crossref_primary_10_3390_v10060336 crossref_primary_10_3389_fimmu_2017_01380 crossref_primary_10_3389_fimmu_2017_01104 crossref_primary_10_1128_JVI_00049_16 crossref_primary_10_2222_jsv_69_129 crossref_primary_10_3389_fendo_2019_00471 crossref_primary_10_1186_s12977_018_0443_0 crossref_primary_10_1016_j_jiph_2018_01_005 crossref_primary_10_1371_journal_ppat_1006825 crossref_primary_10_1371_journal_ppat_1006987 crossref_primary_10_1177_1179555717695548 crossref_primary_10_3389_fimmu_2017_00780 crossref_primary_10_1097_COH_0000000000000893 crossref_primary_10_1080_21645515_2020_1754701 crossref_primary_10_1073_pnas_1520112113 crossref_primary_10_3389_fped_2021_618191 crossref_primary_10_1038_srep29556 crossref_primary_10_1146_annurev_med_091014_090749 crossref_primary_10_3389_fimmu_2020_00252 crossref_primary_10_3389_fimmu_2019_01497 crossref_primary_10_4049_jimmunol_2200145 crossref_primary_10_3389_fimmu_2019_02941 crossref_primary_10_1016_j_tim_2014_12_007 crossref_primary_10_1111_imr_12512 crossref_primary_10_1371_journal_ppat_1005369 crossref_primary_10_3390_ijms19041241 crossref_primary_10_1128_mBio_00317_18 crossref_primary_10_1002_jmv_29381 crossref_primary_10_1111_sji_12868 crossref_primary_10_1126_sciimmunol_aag0851 crossref_primary_10_3389_fimmu_2021_638872 crossref_primary_10_1128_JVI_02278_15 |
Cites_doi | 10.1016/j.cell.2013.03.018 10.1128/JVI.01272-09 10.1586/14760584.5.4.579 10.1128/JVI.73.5.4009-4018.1999 10.1126/science.1207532 10.1084/jem.193.12.1373 10.1097/01.aids.0000432455.06476.bc 10.1089/jir.2005.25.702 10.4049/jimmunol.1002828 10.1002/eji.1830220233 10.1128/JVI.02497-12 10.1128/JVI.01762-08 10.1038/nature12746 10.1016/j.immuni.2013.02.020 10.1038/nm.3109 10.1016/j.cell.2010.10.032 10.1128/JVI.00878-13 10.1146/annurev-immunol-030409-101256 10.1093/intimm/dxt058 10.1084/jem.20091706 10.1084/jem.193.3.297 10.1084/jem.192.11.1545 10.1182/blood-2005-07-2955 10.1128/JVI.01482-09 10.4049/jimmunol.177.7.4927 10.1182/blood-2008-02-140426 10.1172/JCI64314 10.1038/nature12744 10.1128/JVI.01583-08 10.1128/JVI.01679-09 10.1084/jem.20102477 10.1371/journal.ppat.1000433 10.1016/j.chom.2012.09.008 10.1111/j.1365-2249.2011.04465.x 10.1371/journal.ppat.1003853 10.1126/science.1176676 10.1126/science.2658060 10.1084/jem.192.11.1553 10.1038/72309 10.1128/JVI.00598-07 10.1016/j.coi.2012.04.006 10.1146/annurev-immunol-031210-101400 10.1016/j.immuni.2013.08.031 10.1073/pnas.1530509100 10.1128/JVI.02036-08 10.1038/nm1244 10.1128/jvi.68.7.4650-4655.1994 10.1128/JVI.00110-09 10.1371/journal.ppat.1001251 10.1073/pnas.1103012108 10.1021/bi00895a027 10.1126/science.1207227 10.1002/art.25032 10.1097/QAD.0b013e32833243e7 10.1038/nature11604 10.1073/pnas.1214785109 10.1038/nature12053 10.1126/science.8493576 10.1016/S0065-2776(08)60414-9 10.1016/j.immuni.2009.07.002 10.4049/jimmunol.1002955 10.1016/j.immuni.2010.12.012 10.1016/j.immuni.2012.08.012 10.1172/JCI63039 10.1128/JVI.75.17.8340-8347.2001 10.1016/j.virol.2009.10.044 10.1084/jem.20121932 |
ContentType | Journal Article |
Copyright | Copyright © 2014, American Society for Microbiology. All Rights Reserved. Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology |
Copyright_xml | – notice: Copyright © 2014, American Society for Microbiology. All Rights Reserved. – notice: Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7T5 7U9 H94 5PM |
DOI | 10.1128/JVI.02186-14 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1098-5514 |
EndPage | 13321 |
ExternalDocumentID | PMC4249103 25210168 10_1128_JVI_02186_14 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: P01 AI078064 – fundername: NIAID NIH HHS grantid: R01 AI081625 – fundername: NIH HHS grantid: P51 OD010425 – fundername: PHS HHS grantid: NIAID R01AI081625 |
GroupedDBID | --- -~X 0R~ 18M 29L 2WC 39C 4.4 53G 5GY 5RE 5VS 85S AAFWJ AAGFI AAYXX ABPPZ ACGFO ACNCT ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CITATION CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 N9A O9- OK1 P2P RHI RNS RPM RSF TR2 UPT W2D W8F WH7 WOQ YQT ~02 ~KM .55 .GJ 3O- 41~ 6TJ AAYJJ ADXHL AFFNX AI. C1A CGR CUY CVF D0S ECM EIF MVM NPM OHT VH1 X7M Y6R ZGI ZXP 7X8 7T5 7U9 H94 5PM |
ID | FETCH-LOGICAL-c417t-acc7e3d7980c39d8f79e45b5e09ac788241ad65027d14b7f70d2c2cceac456903 |
ISSN | 0022-538X 1098-5514 |
IngestDate | Thu Aug 21 18:10:22 EDT 2025 Fri Jul 11 08:08:22 EDT 2025 Fri Jul 11 12:05:57 EDT 2025 Mon Jul 21 05:36:48 EDT 2025 Tue Jul 01 01:02:34 EDT 2025 Thu Apr 24 23:11:56 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 22 |
Language | English |
License | Copyright © 2014, American Society for Microbiology. All Rights Reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c417t-acc7e3d7980c39d8f79e45b5e09ac788241ad65027d14b7f70d2c2cceac456903 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://jvi.asm.org/content/jvi/88/22/13310.full.pdf |
PMID | 25210168 |
PQID | 1615260116 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4249103 proquest_miscellaneous_1635016098 proquest_miscellaneous_1615260116 pubmed_primary_25210168 crossref_primary_10_1128_JVI_02186_14 crossref_citationtrail_10_1128_JVI_02186_14 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-11-01 |
PublicationDateYYYYMMDD | 2014-11-01 |
PublicationDate_xml | – month: 11 year: 2014 text: 2014-11-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | Journal of virology |
PublicationTitleAlternate | J Virol |
PublicationYear | 2014 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | e_1_3_3_50_2 e_1_3_3_16_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_58_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_56_2 e_1_3_3_33_2 e_1_3_3_54_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_52_2 e_1_3_3_40_2 e_1_3_3_61_2 e_1_3_3_5_2 e_1_3_3_7_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_23_2 e_1_3_3_48_2 e_1_3_3_69_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_67_2 e_1_3_3_44_2 e_1_3_3_65_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 e_1_3_3_63_2 e_1_3_3_51_2 e_1_3_3_17_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_59_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_57_2 e_1_3_3_32_2 e_1_3_3_55_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_53_2 e_1_3_3_62_2 e_1_3_3_60_2 e_1_3_3_6_2 e_1_3_3_8_2 e_1_3_3_28_2 e_1_3_3_49_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_68_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_66_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_64_2 10196297 - J Virol. 1999 May;73(5):4009-18 14214095 - Biochemistry. 1964 Jul;3:996-1008 23720719 - J Virol. 2013 Aug;87(15):8798-804 19906907 - J Virol. 2010 Feb;84(3):1302-13 19906933 - J Virol. 2010 Jan;84(2):953-63 16982935 - J Immunol. 2006 Oct 1;177(7):4927-32 23475201 - Nat Med. 2013 Apr;19(4):494-9 11157050 - J Exp Med. 2001 Feb 5;193(3):297-305 21690411 - Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6 23103874 - Nature. 2012 Dec 6;492(7427):118-22 19439467 - J Virol. 2009 Jul;83(14):7337-48 23540694 - Cell. 2013 Mar 28;153(1):126-38 23552890 - Nature. 2013 Apr 25;496(7446):469-76 23084910 - Cell Host Microbe. 2012 Oct 18;12(4):396-407 19631565 - Immunity. 2009 Sep 18;31(3):457-68 23100539 - Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5 11104798 - J Exp Med. 2000 Dec 4;192(11):1553-62 21764753 - Science. 2011 Sep 16;333(6049):1633-7 18815292 - J Virol. 2008 Dec;82(23):11651-68 24172905 - Nature. 2013 Nov 14;503(7475):224-8 4900673 - Adv Immunol. 1969;10:1-50 8493576 - Science. 1993 May 28;260(5112):1323-7 23254284 - J Exp Med. 2013 Jan 14;210(1):143-56 18922865 - J Virol. 2009 Jan;83(1):188-99 18987148 - J Virol. 2009 Jan;83(2):757-69 21215658 - Immunity. 2011 Jan 28;34(1):108-21 17567707 - J Virol. 2007 Aug;81(16):8793-808 21985363 - Clin Exp Immunol. 2011 Nov;166(2):171-83 11483779 - J Virol. 2001 Sep;75(17):8340-7 21835983 - Science. 2011 Sep 16;333(6049):1593-602 1537385 - Eur J Immunol. 1992 Feb;22(2):511-7 19770692 - AIDS. 2009 Nov 27;23(18):2405-14 10655110 - Nat Med. 2000 Feb;6(2):200-6 19923174 - J Virol. 2010 Feb;84(3):1631-6 11104797 - J Exp Med. 2000 Dec 4;192(11):1545-52 8207839 - J Virol. 1994 Jul;68(7):4650-5 21576382 - J Exp Med. 2011 Jun 6;208(6):1243-52 22595693 - Curr Opin Immunol. 2012 Jun;24(3):316-23 19436712 - PLoS Pathog. 2009 May;5(5):e1000433 21249232 - PLoS Pathog. 2011;7(1):e1001251 24497824 - PLoS Pathog. 2014 Jan;10(1):e1003853 18780835 - Blood. 2008 Dec 1;112(12):4401-10 20192810 - Annu Rev Immunol. 2010;28:413-44 21471443 - J Immunol. 2011 May 15;186(10):5556-68 22922258 - J Clin Invest. 2012 Sep;122(9):3281-94 22999947 - Immunity. 2012 Sep 21;37(3):412-25 19922969 - Virology. 2010 Jan 20;396(2):339-48 23325697 - J Virol. 2013 Apr;87(7):3760-73 12883005 - Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 16989638 - Expert Rev Vaccines. 2006 Aug;5(4):579-95 16318584 - J Interferon Cytokine Res. 2005 Nov;25(11):702-6 22922259 - J Clin Invest. 2012 Sep;122(9):3271-80 24291746 - Int Immunol. 2014 Mar;26(3):183-92 24172896 - Nature. 2013 Nov 14;503(7475):277-80 21270407 - J Immunol. 2011 Mar 1;186(5):2889-96 15880120 - Nat Med. 2005 Jun;11(6):615-22 16384931 - Blood. 2006 Apr 15;107(8):3045-52 20039395 - Arthritis Rheum. 2010 Jan;62(1):234-44 21074050 - Cell. 2010 Nov 12;143(4):592-605 2658060 - Science. 1989 Jun 9;244(4909):1152-7 20048285 - J Exp Med. 2010 Jan 18;207(1):155-71 11413192 - J Exp Med. 2001 Jun 18;193(12):1373-81 21314428 - Annu Rev Immunol. 2011;29:621-63 19628815 - Science. 2009 Aug 21;325(5943):1001-5 24096630 - AIDS. 2013 Oct 23;27(16):2505-17 23583644 - Immunity. 2013 Apr 18;38(4):805-17 24035365 - Immunity. 2013 Oct 17;39(4):758-69 |
References_xml | – ident: e_1_3_3_67_2 doi: 10.1016/j.cell.2013.03.018 – ident: e_1_3_3_12_2 doi: 10.1128/JVI.01272-09 – ident: e_1_3_3_27_2 doi: 10.1586/14760584.5.4.579 – ident: e_1_3_3_14_2 doi: 10.1128/JVI.73.5.4009-4018.1999 – ident: e_1_3_3_65_2 doi: 10.1126/science.1207532 – ident: e_1_3_3_38_2 doi: 10.1084/jem.193.12.1373 – ident: e_1_3_3_52_2 doi: 10.1097/01.aids.0000432455.06476.bc – ident: e_1_3_3_53_2 doi: 10.1089/jir.2005.25.702 – ident: e_1_3_3_40_2 doi: 10.4049/jimmunol.1002828 – ident: e_1_3_3_31_2 doi: 10.1002/eji.1830220233 – ident: e_1_3_3_46_2 doi: 10.1128/JVI.02497-12 – ident: e_1_3_3_2_2 doi: 10.1128/JVI.01762-08 – ident: e_1_3_3_19_2 doi: 10.1038/nature12746 – ident: e_1_3_3_42_2 doi: 10.1016/j.immuni.2013.02.020 – ident: e_1_3_3_48_2 doi: 10.1038/nm.3109 – ident: e_1_3_3_64_2 doi: 10.1016/j.cell.2010.10.032 – ident: e_1_3_3_18_2 doi: 10.1128/JVI.00878-13 – ident: e_1_3_3_24_2 doi: 10.1146/annurev-immunol-030409-101256 – ident: e_1_3_3_58_2 doi: 10.1093/intimm/dxt058 – ident: e_1_3_3_60_2 doi: 10.1084/jem.20091706 – ident: e_1_3_3_62_2 doi: 10.1084/jem.193.3.297 – ident: e_1_3_3_35_2 doi: 10.1084/jem.192.11.1545 – ident: e_1_3_3_56_2 doi: 10.1182/blood-2005-07-2955 – ident: e_1_3_3_3_2 doi: 10.1128/JVI.01482-09 – ident: e_1_3_3_57_2 doi: 10.4049/jimmunol.177.7.4927 – ident: e_1_3_3_54_2 doi: 10.1182/blood-2008-02-140426 – ident: e_1_3_3_51_2 doi: 10.1172/JCI64314 – ident: e_1_3_3_17_2 doi: 10.1038/nature12744 – ident: e_1_3_3_55_2 doi: 10.1128/JVI.01583-08 – ident: e_1_3_3_25_2 doi: 10.1128/JVI.01679-09 – ident: e_1_3_3_63_2 doi: 10.1084/jem.20102477 – ident: e_1_3_3_11_2 doi: 10.1371/journal.ppat.1000433 – ident: e_1_3_3_23_2 doi: 10.1016/j.chom.2012.09.008 – ident: e_1_3_3_61_2 doi: 10.1111/j.1365-2249.2011.04465.x – ident: e_1_3_3_49_2 doi: 10.1371/journal.ppat.1003853 – ident: e_1_3_3_37_2 doi: 10.1126/science.1176676 – ident: e_1_3_3_29_2 doi: 10.1126/science.2658060 – ident: e_1_3_3_36_2 doi: 10.1084/jem.192.11.1553 – ident: e_1_3_3_9_2 doi: 10.1038/72309 – ident: e_1_3_3_22_2 doi: 10.1128/JVI.00598-07 – ident: e_1_3_3_26_2 doi: 10.1016/j.coi.2012.04.006 – ident: e_1_3_3_33_2 doi: 10.1146/annurev-immunol-031210-101400 – ident: e_1_3_3_43_2 doi: 10.1016/j.immuni.2013.08.031 – ident: e_1_3_3_50_2 doi: 10.1073/pnas.1530509100 – ident: e_1_3_3_5_2 doi: 10.1128/JVI.02036-08 – ident: e_1_3_3_21_2 doi: 10.1038/nm1244 – ident: e_1_3_3_59_2 doi: 10.1128/jvi.68.7.4650-4655.1994 – ident: e_1_3_3_6_2 doi: 10.1128/JVI.00110-09 – ident: e_1_3_3_8_2 doi: 10.1371/journal.ppat.1001251 – ident: e_1_3_3_10_2 doi: 10.1073/pnas.1103012108 – ident: e_1_3_3_28_2 doi: 10.1021/bi00895a027 – ident: e_1_3_3_66_2 doi: 10.1126/science.1207227 – ident: e_1_3_3_44_2 doi: 10.1002/art.25032 – ident: e_1_3_3_7_2 doi: 10.1097/QAD.0b013e32833243e7 – ident: e_1_3_3_20_2 doi: 10.1038/nature11604 – ident: e_1_3_3_15_2 doi: 10.1073/pnas.1214785109 – ident: e_1_3_3_32_2 doi: 10.1038/nature12053 – ident: e_1_3_3_13_2 doi: 10.1126/science.8493576 – ident: e_1_3_3_30_2 doi: 10.1016/S0065-2776(08)60414-9 – ident: e_1_3_3_34_2 doi: 10.1016/j.immuni.2009.07.002 – ident: e_1_3_3_41_2 doi: 10.4049/jimmunol.1002955 – ident: e_1_3_3_39_2 doi: 10.1016/j.immuni.2010.12.012 – ident: e_1_3_3_68_2 doi: 10.1016/j.immuni.2012.08.012 – ident: e_1_3_3_45_2 doi: 10.1172/JCI63039 – ident: e_1_3_3_69_2 doi: 10.1038/nature12053 – ident: e_1_3_3_16_2 doi: 10.1128/JVI.75.17.8340-8347.2001 – ident: e_1_3_3_4_2 doi: 10.1016/j.virol.2009.10.044 – ident: e_1_3_3_47_2 doi: 10.1084/jem.20121932 – reference: 8207839 - J Virol. 1994 Jul;68(7):4650-5 – reference: 21270407 - J Immunol. 2011 Mar 1;186(5):2889-96 – reference: 19906907 - J Virol. 2010 Feb;84(3):1302-13 – reference: 23100539 - Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5 – reference: 24497824 - PLoS Pathog. 2014 Jan;10(1):e1003853 – reference: 23552890 - Nature. 2013 Apr 25;496(7446):469-76 – reference: 20192810 - Annu Rev Immunol. 2010;28:413-44 – reference: 20039395 - Arthritis Rheum. 2010 Jan;62(1):234-44 – reference: 11157050 - J Exp Med. 2001 Feb 5;193(3):297-305 – reference: 21690411 - Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6 – reference: 22595693 - Curr Opin Immunol. 2012 Jun;24(3):316-23 – reference: 8493576 - Science. 1993 May 28;260(5112):1323-7 – reference: 24035365 - Immunity. 2013 Oct 17;39(4):758-69 – reference: 10655110 - Nat Med. 2000 Feb;6(2):200-6 – reference: 18987148 - J Virol. 2009 Jan;83(2):757-69 – reference: 20048285 - J Exp Med. 2010 Jan 18;207(1):155-71 – reference: 18922865 - J Virol. 2009 Jan;83(1):188-99 – reference: 21471443 - J Immunol. 2011 May 15;186(10):5556-68 – reference: 15880120 - Nat Med. 2005 Jun;11(6):615-22 – reference: 23720719 - J Virol. 2013 Aug;87(15):8798-804 – reference: 24096630 - AIDS. 2013 Oct 23;27(16):2505-17 – reference: 23325697 - J Virol. 2013 Apr;87(7):3760-73 – reference: 24172905 - Nature. 2013 Nov 14;503(7475):224-8 – reference: 10196297 - J Virol. 1999 May;73(5):4009-18 – reference: 21835983 - Science. 2011 Sep 16;333(6049):1593-602 – reference: 11104798 - J Exp Med. 2000 Dec 4;192(11):1553-62 – reference: 14214095 - Biochemistry. 1964 Jul;3:996-1008 – reference: 16318584 - J Interferon Cytokine Res. 2005 Nov;25(11):702-6 – reference: 16982935 - J Immunol. 2006 Oct 1;177(7):4927-32 – reference: 21215658 - Immunity. 2011 Jan 28;34(1):108-21 – reference: 21576382 - J Exp Med. 2011 Jun 6;208(6):1243-52 – reference: 21074050 - Cell. 2010 Nov 12;143(4):592-605 – reference: 4900673 - Adv Immunol. 1969;10:1-50 – reference: 18815292 - J Virol. 2008 Dec;82(23):11651-68 – reference: 19628815 - Science. 2009 Aug 21;325(5943):1001-5 – reference: 16384931 - Blood. 2006 Apr 15;107(8):3045-52 – reference: 19436712 - PLoS Pathog. 2009 May;5(5):e1000433 – reference: 23540694 - Cell. 2013 Mar 28;153(1):126-38 – reference: 23254284 - J Exp Med. 2013 Jan 14;210(1):143-56 – reference: 19770692 - AIDS. 2009 Nov 27;23(18):2405-14 – reference: 19439467 - J Virol. 2009 Jul;83(14):7337-48 – reference: 11413192 - J Exp Med. 2001 Jun 18;193(12):1373-81 – reference: 18780835 - Blood. 2008 Dec 1;112(12):4401-10 – reference: 21764753 - Science. 2011 Sep 16;333(6049):1633-7 – reference: 23084910 - Cell Host Microbe. 2012 Oct 18;12(4):396-407 – reference: 22999947 - Immunity. 2012 Sep 21;37(3):412-25 – reference: 11483779 - J Virol. 2001 Sep;75(17):8340-7 – reference: 2658060 - Science. 1989 Jun 9;244(4909):1152-7 – reference: 22922259 - J Clin Invest. 2012 Sep;122(9):3271-80 – reference: 24291746 - Int Immunol. 2014 Mar;26(3):183-92 – reference: 17567707 - J Virol. 2007 Aug;81(16):8793-808 – reference: 21985363 - Clin Exp Immunol. 2011 Nov;166(2):171-83 – reference: 24172896 - Nature. 2013 Nov 14;503(7475):277-80 – reference: 21314428 - Annu Rev Immunol. 2011;29:621-63 – reference: 19906933 - J Virol. 2010 Jan;84(2):953-63 – reference: 23475201 - Nat Med. 2013 Apr;19(4):494-9 – reference: 1537385 - Eur J Immunol. 1992 Feb;22(2):511-7 – reference: 23583644 - Immunity. 2013 Apr 18;38(4):805-17 – reference: 19923174 - J Virol. 2010 Feb;84(3):1631-6 – reference: 19922969 - Virology. 2010 Jan 20;396(2):339-48 – reference: 21249232 - PLoS Pathog. 2011;7(1):e1001251 – reference: 12883005 - Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 – reference: 16989638 - Expert Rev Vaccines. 2006 Aug;5(4):579-95 – reference: 23103874 - Nature. 2012 Dec 6;492(7427):118-22 – reference: 22922258 - J Clin Invest. 2012 Sep;122(9):3281-94 – reference: 19631565 - Immunity. 2009 Sep 18;31(3):457-68 – reference: 11104797 - J Exp Med. 2000 Dec 4;192(11):1545-52 |
SSID | ssj0014464 |
Score | 2.403284 |
Snippet | Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 13310 |
SubjectTerms | Antibodies, Neutralizing - blood B-Lymphocytes - immunology Cellular Response to Infection Cohort Studies HIV Antibodies - blood HIV Infections - immunology HIV-1 - immunology Human immunodeficiency virus 1 Humans Longitudinal Studies Programmed Cell Death 1 Receptor - analysis Receptors, CXCR5 - analysis T-Lymphocyte Subsets - chemistry T-Lymphocyte Subsets - immunology T-Lymphocytes, Helper-Inducer - chemistry T-Lymphocytes, Helper-Inducer - immunology |
Title | Early Preservation of CXCR5 + PD-1 + Helper T Cells and B Cell Activation Predict the Breadth of Neutralizing Antibody Responses in Chronic HIV-1 Infection |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25210168 https://www.proquest.com/docview/1615260116 https://www.proquest.com/docview/1635016098 https://pubmed.ncbi.nlm.nih.gov/PMC4249103 |
Volume | 88 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECWMFAV6KbrX3cACzUlQKlGSJR9td3GCuggKJ_BNEBchAhzZSORD8yf9zX5BZ0hKppumaHORZYkmbc_jcN5oZkjIuwgWOS5j6QcZT_y45NwvsrD0UxkVPE1UqALMRp59HUxP4qNFsuj1fjpRS5uGH4irP-aV3EaqcA3kilmy_yHZrlO4AOcgXziChOH4TzI21YkxiqJ1reroisXkW7LPxt7xBz_EV1ha1urCm3sTtVyamsxjfe6NRLu7GfYiK9HYgAGQfHOmvQlqo30hV9p9UjcVX0k023VkrQ7m8mx9XW96eOqHoHBMdFd9g9mLeXWuJ7_LD9HqZpuYNlo2pd09ewaTcXPp3DAw-4wUovMQNQXY3kVjoga_KPhGstjxaYSxTe7rUNg-rHIjV2fVtjKVq9GRTEd6e2JYz4wSxxqpaAm6Wj7LHDSbVGirs4Gl28ha1b43SdvXVxeGGRNHp4cHeisv34zgAG19rpHGwCYCUzrbrrFd5OPxbBID4w2xQO0dBtSGtR4m--QL6HncVrjH39Uma7DsvTswFrG2o-xaVNdo0u_Rvo75NH9A7lsA0JEB8UPSU_UjctfshPr9MfmhoUxdKNNVSTWUPYpA9qiBMZ1TDWMKMKZjfU63MKYWxhRgTC2MsSMXxrSFMe1gTKuaWhhTDWPawfgJOfn0cT6Z-nbXEF_EYdr4hRCpimQ6zAIRDWVWpkMVJzxRwbAQKRDKOCwk8BKWyjDmaZkGkgkmBFggQCaGQfSU7NWrWj0nVIqMlaIoQgFgSuSAKyw9FUdKBYwDNekTr_3nc2FL6uPOLstcU2uW5SCyXIsMKHaf7Het16aUzA3t3rZCzEHX4wO8olarzWWO7AxLAIaDv7XBUIEBTIE-eWYE343WIqZP0h1IdA2w1vzunbo60zXnLWhf3PqTL8k9mOmZiQR7Rfaai416DfZ8w9_oCfALY-b4Kw |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+Preservation+of+CXCR5%2B+PD-1%2B+Helper+T+Cells+and+B+Cell+Activation+Predict+the+Breadth+of+Neutralizing+Antibody+Responses+in+Chronic+HIV-1+Infection&rft.jtitle=Journal+of+virology&rft.au=Cohen%2C+Kristen&rft.au=Altfeld%2C+Marcus&rft.au=Alter%2C+Galit&rft.au=Stamatatos%2C+Leonidas&rft.date=2014-11-01&rft.pub=American+Society+for+Microbiology&rft.issn=0022-538X&rft.eissn=1098-5514&rft.volume=88&rft.issue=22&rft.spage=13310&rft.epage=13321&rft_id=info:doi/10.1128%2FJVI.02186-14&rft_id=info%3Apmid%2F25210168&rft.externalDocID=PMC4249103 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon |